Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Garufi, C.
Right arrow Articles by Terzoli, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garufi, C.
Right arrow Articles by Terzoli, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:179-182, 2001
© 2001 European Society for Medical Oncology

research-article

Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

C. Garufi1,, C. Nisticò2, A. Vaccaro1, A. D'Ottavio1, A. R. Zappalà1, A. M. Aschelter1 and E. Terzoli1

1Service of Complementary Medical Oncology. Regina Elana Cancer Institute Rome, Italy
2Debioclinic, Charenton-Le-Pont, France

Oncobogia Medica Complementare Istituto Regina Elena Via E. Chianesi 53 00144 Roma Italygarufi{at}sirio-oncology.it

PURPOSE:: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients.

PATIENTS AND METHODS:: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed.

RESULTS:: The median number of courses per patient was four (range 2–6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5–43.3) which represents 100% of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21%), (95% con fidence interval (CI): 0%–43%), two stable disease (14%) and nine progressed (64%). Response lasted five, four and five months respectively. Median survival was 12months.

CONCLUSIONS:: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluorouracil (5-FU). anthracyclines and taxanes should represent the next step of development of this new drug.

breast cancer, oxaliplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. L. Spunt, B. B. Freeman III, C. A. Billups, V. McPherson, R. B. Khan, C. B. Pratt, and C. F. Stewart
Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors
J. Clin. Oncol., June 1, 2007; 25(16): 2274 - 2280.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al.
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
Ann. Onc., February 1, 2003; 14(2): 304 - 312.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.